Abstract
Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 X 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of new anthracycline antibiotic.
MeSH terms
-
Aged
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Daunorubicin / adverse effects
-
Daunorubicin / analogs & derivatives*
-
Daunorubicin / therapeutic use
-
Drug Evaluation
-
Female
-
Gastrointestinal Diseases / chemically induced
-
Hematologic Diseases / chemically induced
-
Humans
-
Idarubicin
-
Middle Aged
-
Neoplasm Metastasis